What is Lu PSMA (Lutetium-Prostate Specific Membrane Antigen) Therapy?

Lu177 PSMA Therapy is a treatment for patients with prostate cancer, especially those who have become refractory to conventional therapy. Lutetium PSMA therapy helps to slow down the growth of the cancer cells, reduce the size of the tumours and most importantly improve the quality of life of the patients by reducing the pain caused by the cancer.

Many prostate cancers, in particular those that have spread or become resistant to hormonal therapies, express a unique receptor on their cell surface called Prostate Specific Membrane Antigen (PSMA). When Prostate Cancer metastasizes i.e. spreads to other parts of the body, the PSMA receptor is expressed over the sites of metastases as well.

How does Lu PSMA Therapy Work?

Lutetium-177 is a radioactive substance that emits beta radiation, a destructive kind of radiation. Lutetium-177 is bound to a small peptide which attaches to the PSMA receptor expressed on the cancer cell surface. The Lutetium 177 – PSMA complex, thus attached to the prostate cancer cell, then emits killing radiation causing cell death of the cancer cell. Since the penetration of the emitted beta particle is very small, the surrounding normal cells are spared.

How is the Therapy Done?

Lu177 PSMA is administered intravenously. The patient is admitted to the hospital for 24 hours. A kidney function scan called a MAG3/EC scan is done prior to the administration of the Lu177 PSMA.

What are the Side Effects of Lu PSMA Therapy?

Lu177 PSMA is well tolerated. The most common side effects are a slightly dry mouth, fatigue and nausea. There may also be a slight fall in the white blood cells and platelets about 2 – 3 weeks after the Lu177 PSMA administration.

What is the Response Rate With Lu PSMA Therapy?

The response rates of Lu177 PSMA depend on the tumour biology of prostate cancer, the initial Gleason Score, the extent of disease and the responses to prior therapies. Typically, more than 70% of patients demonstrate a reduction in S. PSA and a shrinkage of tumours following Lu177 PSMA therapy.

When would the doctor consider using this Therapy?

Lu PSMA Therapy is a very specific therapy and is used for managing metastatic Prostate Cancer or when Prostate Cancer is no longer responsive to other types of treatment.

What are the Treatment Schedules with Lu PSMA Therapy?

Most patients undergo three-four treatment cycles at intervals of 8-12 weeks. The number of cycles and the interim duration may vary between individuals depending on the response and interim assessments.

Why should I choose the nuclear medicine therapy center at Fortis Memorial & Research Institute (FMRI), Gurugram (Haryana, India)?

The Nuclear Medicine Therapy Centre at FMRI was one of the first institutes to offer Radio-ligand Therapy with Lu PSMA, and today, the center receives patients from the country and from across the world.

Choose Your Language:

Home >
Gallery

Featured

where is Terbium sourced from, terbium source, terbium supply

Terbium-161 Therapy, Is the supply of Terbium-161 stable, How is Terbium-161 therapy administered, What is the role of dosimetry scans with Terbium-161, How many cycles of Tb-161 therapy are needed, What are the benefits of Tb-161 over Lutetium-177, Can Tb-161 help patients who did not respond to Lu-177, What is the VIOLET study and what does it tell us about Tb-161, Could Terbium-161 replace Lutetium-177 in the future

TARE for liver cancer, Transarterial radioembolization liver transplant, Yttrium-90 treatment for HCC, Liver cancer downstaging for transplant, TARE vs TACE for hepatocellular carcinoma, Bridging therapy for liver transplant, Radioembolization survival rates post-transplant, Cost-effectiveness of TARE for liver cancer, Y-90 therapy for liver cancer patients, HCC treatment before liver transplantation, Dr. Ishita B Sen

psa level, Raised psa what does it means, raised PSA value, psa alone is not enough

how is prostate cancer diagnosed, psa level, Raised psa what does it means, raised PSA value

psa level, Raised psa what does it means, raised PSA value

Alpha PRRT vs Beta PRRT, Actinium-225 PRRT for neuroendocrine tumors, Targeted alpha therapy NETs, Alpha-emitting radionuclide therapy, Lu-177 resistance in NET treatment, High LET radiation therapy NETs, PRRT with Actinium-225 vs Lutetium-177, Alpha PRRT clinical trials, Dr. Ishita B Sen

Lu-177 PSMA therapy, Lutetium-177 prostate cancer treatment, PSMA-targeted radiotherapy, Advanced prostate cancer treatment, Metastatic prostate cancer therapy, Lu-177 PSMA efficacy, Prostate cancer nuclear medicine, Lu-177 PSMA therapy India, Prostate cancer radioligand therapy, Best hospital for Lu-177 PSMA therapy, Dr. Ishita B Sen

Lutetium-177 therapy, Actinium-225 therapy, Terbium-161 therapy, PSMA-targeted therapy, Radioligand therapy, Prostate cancer treatment, Metastatic castration-resistant prostate cancer ,Alpha particle therapy, Beta particle therapy, Nuclear medicine in oncology, Dr. Ishita B Sen

Lutetium-177 therapy, Lu-177 PSMA treatment, Alpha PSMA therapy, Actinium-225 therapy, Terbium-161 therapy, Prostate cancer nuclear therapy, Advanced nuclear medicine, PSMA-targeted therapy, Best nuclear medicine doctor India, Nuclear medicine treatment Gurugram, Radioisotope therapy for cancer, Yttrium-90 radioembolization, Cancer treatment India, Free second opinion cancer therapy

Second Opinion by Dr Ishita B Sen, Lutetium-177 therapy, Lu-177 PSMA treatment, Alpha PSMA therapy, Actinium-225 therapy, Terbium-161 therapy, Prostate cancer nuclear therapy, Advanced nuclear medicine, PSMA-targeted therapy, Best nuclear medicine doctor India, Nuclear medicine treatment Gurugram, Radioisotope therapy for cancer, Yttrium-90 radioembolization, Cancer treatment India, Free second opinion cancer therapy

ransarterial radioembolization, TARE for liver cancer, liver transplant bridge, metastatic liver disease treatment, TARE with chemotherapy, yttrium spheres therapy

Lutetium PSMA therapy, Pluvicto therapy, metastatic prostate cancer treatment, hormone-positive prostate cancer, upfront PSMA therapy, advanced prostate cancer care

lutetium 177 psma, lutetium therapy, lutetium therapy, lutetium PSMA therapy, pluvicto therapy, treatment for prostate cancer, Lutetium PSMA therapy

Lutetium PSMA therapy, Pluvicto therapy, personalized dosimetry, dosimetry scans, metastatic prostate cancer treatment, nuclear medicine, critical organ protection

PSA levels, Pluvicto therapy monitoring, Lutetium PSMA therapy, prostate cancer treatment, PSA response, clinical response, prostate cancer markers

Lutetium-177Lu, Pluvictotherapy, Lutetium Therapy, PSMA Therapy, lu177 PSMA Therapy, Prostate Cancer, Metastatic Cancer Treatment

Lutetium-177, PSMA Therapy, Prostate Cancer, Metastatic Treatment, Cancer Therapy, lutetium 177 psma therapy, lu177 psma therapy, treatment for metastatic prostate carcinoma

Lutetium PRRT, Neuroendocrine Tumors, Cancer Treatment, Theranostics, lutetium prrt for metastatic

Radioligand therapy cost comparison, Affordable cancer treatment India, Lutetium-177 PSMA therapy pricing, Actinium-225 PSMA therapy cost, Transarterial radioembolization Yttrium-90 cost, Global cancer therapy cost analysis

161Tb Auger electrons, PSMA ligands, Prostate cancer, Radioligand therapy

effect of psma therapy, adverse effect of psma therapy, what are the adverse effects of psma therapy

PSMA Therapy, Prostate Cancer, Prrt therapy for protstate cancer

All Prostate Cancers Express PSMA, prostate cancer tereatment, prostate cancer

Alpha PSMA therapy, Prostate cancer treatment, Actinium-225 therapy, Targeted radiation therapy, Lutetium-177 vs Alpha emitters, PSMA radiopharmaceuticals

$Neuroendocrine Tumors Are Often Refractory to Chemotherapy$

Peptide Receptor Radionuclide Therapy (PRRT), PRRT for neuroendocrine tumors, Lutetium-177 PRRT therapy, Lutetium PRRT treatment success rate, Targeted therapy with Lutetium-177, Lutetium-177 for neuroendocrine tumors, Lutetium PRRT vs chemotherapy, PRRT side effects with Lutetium-177, Advanced neuroendocrine tumor treatment with Lutetium PRRT, Lutetium PRRT therapy for metastatic NETs, PRRT with Lutetium-177 cost, Lutetium-177 PRRT procedure, Lutetium PRRT therapy survival rates

Yttrium-90 treatment for liver cancer, Y-90 radioembolization, Liver cancer treatment options, Unresectable liver cancer therapy, Selective internal radiation therapy (SIRT), Y-90 microspheres liver cancer, Yttrium-90 procedure for hepatocellular carcinoma, Y-90 therapy success rate, Yttrium-90 cost India, Advanced liver cancer radiation treatment, Yttrium-90 survival rate liver cancer, Side effects of Y-90 treatment, Y-90 radioembolization vs TACE, Best treatment for liver metastases, Yttrium-90 downstaging liver cancer

what is prrt, post prrt treatment, prrt treatment, prrt cancer therapy, lutetium prrt, prrt cancer treatment, prrt in neuroendocrine tumors, PRRT treatment cost, Neuroendocrine Cancer Treatment in India, Neuroendocrine Cancer Treatment, Peptide Receptor Radionuclide Therapy in India, PRRT Treatment for Neuroendocrine Tumors

What is the best Erectile Medication After Prostatectomy

How Soon Can You take Viagra after Prostate Surgery

How is the Sex life of Prostate Cancer Patients after Lutetium After Lutetium Therapy

How do You Pleasure a Man after Prostate Surgery

Can you live for 20 years after prostate removal?

Lu 177 PRRT, Tandem Therapy, Nuclear Medicine Expert in India, Nuclear Medicine Therapy, Nuclear Medicine Therapy in India, radioligand therapy, lutetitium177, lutetium therapy india, pluvicto, actinium 225, actinium 225 therapy, actinium therapy, PSMA therapy, Alpha therapy, PRRT therapy, PRRT, radioisotope labeling, radioligand labeling, nuclear medicine therapy india, prostate cancer, neuroendocrine tumours, nuclear medicine for cancer, advanced cancer treatment, prostrate cancer treatment, neuroendocrine tumour treatment, prostate cancer treatment india, neuroendocrine tumour treatment india, dr ishita sen, dr ishita b sen, treatment for castration resistant prostate cancer

lutetium psma therapy, lutetium 177 treatment, psma therapy, lutetium 177 PSMA therapy radioligand therapy, lutetium 177, lutetium therapy india, pluvicto, actinium 225, actinium225 therapy, actinium therapy, PSMA therapy, Alpha therapy, PRRT therapy, PRRT, radioisotope labelling, radioligand labelling, nuclear medicine therapy

Transarterial Radioembolisation, Transarterial Chemoembolization, TACE vs TARE, Transarterial Radioembolisation in India, Side Effects of TARE, Nuclear Medicine Expert in India

Actinium Ac 225 Alpha PRRT, PRRT in India, Peptide Receptor Radionuclide Therapy in India, Nuclear Medicine Expert in India, PRRT Treatment for Neuroendocrine Tumors, PRRT Therapy Side Effects, PRRT Therapy, PRRT Treatment, PRRT in Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy

Transarterial Radioembolisation, Transarterial Radioembolisation in India, Side Effects of TARE, TACE vs TARE, PRRT, PRRT in India, PRRT in Neuroendocrine Tumors, PRRT Therapy, PRRT Therapy Side Effects, PRRT Treatment, PRRT Treatment Cost in India, PRRT Treatment for Neuroendocrine Tumors

Psma Therapy, what is PSMA therapy, prostate cancer, lutetium PSMA, nuclear medicine therapy, nuclear medicine expert in india, psma therapy in india radioligand therapy, lutetitium177

Tare procedure, Tare treatment procedure, OMT for TARE, Transarterial Radioembolization, Trans arterial Radioembolization Cost in India, liver cancer treatment radioligand therapy, lutetitium177, lutetitium therapy india, pluvicto, actinium225, actinium225 therapy, actinium therapy, PSMA therapy, Alphatherapy, PRRTtherapy, PRRT

ADT, Androgen Deprivation Therapy, ADT Side effects, Hormone Sensitive metastatic Prostate Cancer, Lu177 PSMA Therapy, LU177 Therapy for Prostate Cancer in India, Lutetium Therapy for Prostate Cancer in India, Lu177 Treatment in India, PSMA Therapy in India, Lutetium Therapy in India

radioligand therapy, radioligand therapy novartis, radioligand therapy and, labelling radioligand, labelling radioligand levels, labelling radioligand and, radioisotope therapy, radioisotope therapy

Transarterial Radioembolisation, Transarterial Chemoembolization, TACE vs TARE

Hormone Sensitive metastatic Prostate Cancer, Lu177 PSMA Therapy, LU177 Therapy for Prostate Cancer in India

lutetium psma therapy, lutetium 177 treatment, psma therapy, lutetium 177 PSMA therapy radioligand therapy, lutetium 177

PRRT effectiveness, PRRT side effects, PRRT vs other treatments, NETs treatment options, Somatostatin receptor targeting, Hormone-secreting neoplasms, Advanced NETs, Neuroendocrine tumors (NETs), Peptide Receptor Radionuclide Therapy (PRRT), Somatostatin analogs, Metastatic NETs, What is PRRT, nuclear medicine therapy, PRRT Treatment in India

Dry mouth after nuclear medicine therapy, Xerostomia after Actinium-225 therapy, Ac-225 therapy side effects - dry mouth, Nuclear medicine side effects - dry mouth, Managing dry mouth after PSMA therapy, Botox for dry mouth after nuclear medicine, Preventing dry mouth during nuclear medicine treatment, Salivary gland protection during nuclear medicine therapy, Improving quality of life with nuclear medicine cancer treatment, Coping with side effects of nuclear medicine therapy

Radiotheranostics, Personalized cancer care, Nuclear medicine, Prostate cancer treatment, Neuroendocrine tumors, Ga68 PSMA PET scan, Lu177 PSMA therapy, PRRT, Alpha-emitting radionuclides, Targeted alpha therapy, Actinium-225, Fortis Memorial Research Institute, Cancer diagnostics and therapeutics, Advanced cancer treatment India, Molecular imaging in oncology, Precision Medicine

Nuclear medicine therapy side effects, Lutetium-177 therapy side effects, Actinium-225 treatment side effects, Yttrium-90 PRRT side effects, Managing side effects of nuclear medicine, Bone marrow suppression in nuclear medicine, Renal toxicity in Lutetium-177 therapy, Fatigue from nuclear medicine treatments, Hematological toxicity in Actinium-225 therapy, Gastrointestinal side effects of Y-90 PRRT, Radiation-induced side effects in cancer therapy, Long-term effects of nuclear medicine, Preventing side effects in cancer radiation therapy, Nausea and vomiting in nuclear medicine, Kidney damage risk in nuclear medicine treatments

Medical imaging, Cancer diagnosis, Cancer treatment, PET scan, Radiology, Oncology, Nuclear medicine, Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), Gamma camera, DOTATATE scan, DOTANOC scan, Radioisotopes, Radiotracers, Theranostics, Precision oncology, Hybrid imaging, Improved sensitivity & resolution, Faster scanning, Siemens Healthineers, Biograph Vision, Prostate cancer diagnosis, Neuroendocrine tumors, Treatment monitoring, Early cancer detection

Prostate cancer early detection, Prostate cancer screening, Nuclear medicine in prostate cancer, Prostate cancer diagnostics, Prostate-Specific Antigen (PSA),Prostate cancer risk factors, Prostate cancer treatment advancements, Prostate cancer support groups, Prostate cancer awareness activities, Blue ribbon for prostate cancer, Prostate cancer educational workshops, Prostate cancer public awareness campaigns, Prostate cancer research fundraising, Run for Dad prostate cancer events, Global prostate cancer awareness, Prostate cancer prevention, Advancements in prostate cancer treatment, Prostate cancer webinars, Prostate cancer and nuclear oncology

Nuclear medicine, Cancer treatment, Targeted therapy, Theranostics, Radioisotopes, PET scan, Lutetium-177 (Lu-177), Pluvicto, Actinium-225 (Ac-225), Yttrium-90 (Y-90), Radioembolization (TARE), Transarterial Radioemobolization, Prostate cancer, Liver cancer, Nuclear medicine advantages over conventional cancer treatment, How does nuclear medicine detect cancer?, What is theranostics in cancer treatment?, Role of Lutetium-177 in prostate cancer treatment, Actinium-225 and alpha therapy for cancer, Y-90 radioembolization for liver cancer, Future of nuclear medicine in oncology

Pluvicto therapy, Lutetium-177 treatment, Prostate cancer treatment, Advanced prostate cancer options, Metastatic castration-resistant prostate cancer (mCRPC), Targeted nuclear medicine therapy, PSMA-targeted therapy, Prostate cancer survival rates, Actinium-225 prostate cancer, Lead-212 cancer treatment, Innovative cancer therapies, Prostate cancer quality of life, Nuclear medicine in prostate cancer, Prostate cancer clinical trials, Cutting-edge prostate cancer treatment

Consult Dr Ishita B Sen

Get in
touch with us

Upload Reports(Max file size 100mb) Liver Function Test, Pet Scan, Pet Scan (DICOM Or Any), PSA Test, Blood Test, Kidney Function Test, Bone Marrow Examination, Medical History

BOOK AN APPOINTMENT

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

Featured

Consult Dr Ishita B Sen

Get in touch with us

Get in
touch with us